News AbbVie taking on Gilead with eight-week hep C course Latest combination drug resulted in 97.5% cure rates across all major disease strains
News Oxford Uni joins biotech Evotec in R&D partnership University creates partnership with German biotech.
News BMS and Infinity look to boost Opdivo in lung cancer Companies look for combinations in lung cancer and other tumours.
Roche Roche muscling into melanoma with Tecentriq Swiss pharma looking to combine immunotherapy with already marketed drugs.
News Women urged to look for "non-lump" breast cancer symptoms Patients with "non lump" symptoms more likely to delay doctor visit.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
